# Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines

> **NCT03481816** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 18 (actual)

## Conditions studied

- Prostatic Neoplasms
- Prostatic Cancer

## Interventions

- **BIOLOGICAL:** ETBX-071; adenoviral PSA vaccine
- **BIOLOGICAL:** ETBX-061; adenoviral MUC1 vaccine
- **BIOLOGICAL:** ETBX-051; adenoviral brachyury vaccine

## Key facts

- **NCT ID:** NCT03481816
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-24
- **Primary completion:** 2020-01-15
- **Final completion:** 2021-03-09
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2021-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03481816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03481816, "Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03481816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*